Law360, New York (October 07, 2008, 12:00 AM ET) -- Eli Lilly & Co. said Tuesday that it would pay $62 million to settle allegations made by 32 states and the District of Columbia that it improperly marketed and promoted blockbuster anti-psychotic Zyprexa.
The attorneys general alleged that Lilly marketed Zyprexa for uses that the U.S. Food and Drug Administration had not approved. The company also allegedly failed to adequately disclose the drug’s potential side effects to health care providers.
In settling, Lilly agreed to not promote Zyprexa for off-label uses. Lilly also agreed to detail...
Lilly Settles Zyprexa State Claims In $62M Deal
To view the full article, take a free trial now.
